JadiCell™ [umbilical cord derived MSC] was shown to significantly improve survival in COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS) and also reduce lung scarring associated with long-COVID-19.
Interestingly, The company has also filed for a patent demonstrating that the US Food and Drug Administration (FDA) cleared drug, lithium carbonate (sold under the names Lithobid® and Eskalith®) substantially augments the scar inhibiting activity of JadiCell.
https://www.europeanpharmaceuticalreview.com/news/155159/stem-cell-therapy-shows-promise-in-covid-19-respiratory-distress/
Maybe MSB will include some long-COVID endpoints in their next phase III trial (lung scarring etc). Looks like promising data should prevail which would also be relevant to All Cause ARDS in my opinion.
Good luck patient holders!!!
New Covid 19 treatment, page-172
-
- There are more pages in this discussion • 273 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.080(8.42%) |
Mkt cap ! $1.176B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | $1.03 | 95.0¢ | $43.38M | 42.28M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 72752 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 205100 | 2 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |